{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:40:34Z","timestamp":1790905234092,"version":"4.1.0"},"reference-count":42,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inhibitor available for use in combination with low-dose cytarabine (LDAC). Data Sources: PubMed and relevant congress abstracts were searched using the term \u201cglasdegib\u201d. In addition, based on our experience with glasdegib, we considered treatment aspects of particular relevance to pharmacists and advanced practitioners. Data Summary: In a randomized phase II study, the combination of glasdegib plus LDAC demonstrated superior overall survival versus LDAC alone (hazard ratio 0.51, 80% confidence interval 0.39\u20130.67, p\u2009=\u20090.0004). The trial reported adverse events (AEs) of special relevance for older patients, such as hematologic events, gastrointestinal toxicity, and fatigue, as well as AEs associated with Hh-pathway inhibitors (alopecia, muscle spasms, dysgeusia). Educating patients about typical AEs can facilitate adherence as well as early AE identification and proactive management. For LDAC, which is a long-established therapy in AML, various stages of delivery need consideration, with attention to individual circumstances. Practical measures such as dispensing a longer supply can reduce the number of return clinic visits, providing a meaningful difference for many patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pharmacists and advanced practitioners play important roles in treatment with glasdegib plus LDAC. Ultimately, framing plans for treatment delivery within the individual circumstances of each patient may enable them to stay on therapy longer, giving them the greatest potential to achieve benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220973737","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T08:48:25Z","timestamp":1605862105000},"page":"658-672","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1476-5747","authenticated-orcid":false,"given":"Valerie","family":"Relias","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Tufts Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-5554","authenticated-orcid":false,"given":"Matthew J","family":"Newman","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Hospital Department of Pharmacy, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Pharmacy at the University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyedeh","family":"Saneeymehri","sequence":"additional","affiliation":[{"name":"Emory University Hospital\/Winship Cancer Institute, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genique","family":"Stanislaus","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tobin","sequence":"additional","affiliation":[{"name":"Blood Disorders Center, University of Colorado Hospital, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J","family":"Hoang","sequence":"additional","affiliation":[{"name":"Pfizer Oncology, Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne C","family":"Ryan","sequence":"additional","affiliation":[{"name":"Pfizer Oncology, Pfizer Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilene","family":"Galinsky","sequence":"additional","affiliation":[{"name":"Department of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"bibr1-1078155220973737","unstructured":"National Cancer Institute. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Leukemia\u2009\u2212\u2009acute myeloid leukemia (AML), https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html (accessed 24 July 2019)."},{"key":"bibr2-1078155220973737","unstructured":"National Comprehensive Cancer Network. Acute myeloid leukemia (version 2.2020), www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf (password protected, accessed 16 October 2019)."},{"key":"bibr3-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.03.011"},{"key":"bibr4-1078155220973737","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10070225"},{"key":"bibr5-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"bibr6-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9178"},{"key":"bibr7-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22496"},{"key":"bibr8-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856"},{"key":"bibr9-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9429"},{"key":"bibr10-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32439"},{"key":"bibr11-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0312-9"},{"key":"bibr12-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110934"},{"key":"bibr13-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000559300.20719.08"},{"key":"bibr14-1078155220973737","unstructured":"Pfizer. DAURISMO\u2122 (glasdegib) tablets, for oral use. US prescribing information revised March 2020. Initial US approval November 2018, www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210656s002s004lbl.pdf (accessed 11 June 2020)."},{"key":"bibr15-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.375"},{"key":"bibr16-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0277-7"},{"key":"bibr17-1078155220973737","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10879"},{"key":"bibr18-1078155220973737","doi-asserted-by":"publisher","DOI":"10.4172\/1948-5956.1000462"},{"key":"bibr19-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13019"},{"key":"bibr20-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0365"},{"key":"bibr21-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21723"},{"key":"bibr22-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0186"},{"key":"bibr23-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1188\/12.CJON.E173-E177"},{"key":"bibr24-1078155220973737","unstructured":"National Comprehensive Cancer Network. Antiemesis (version 2.2020), www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf (password protected, accessed 8 June 2020)."},{"key":"bibr25-1078155220973737","unstructured":"National Institutes of Health. U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). Version 5.0, https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (2017, accessed 19 July 2019)."},{"key":"bibr26-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3748-8"},{"key":"bibr27-1078155220973737","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S187409"},{"key":"bibr28-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3420-8"},{"key":"bibr29-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-746420"},{"key":"bibr30-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00096-4"},{"key":"bibr31-1078155220973737","first-page":"3","volume":"45","author":"Shaik N","year":"2018","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"bibr32-1078155220973737","unstructured":"Pfizer. Data on file. BRIGHT AML study unpublished data."},{"key":"bibr33-1078155220973737","unstructured":"Indiana University. Drug interactions flockhart table\u2122, https:\/\/drug-interactions.medicine.iu.edu\/Main-Table.aspx (accessed 30 August 2019)."},{"key":"bibr34-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13568"},{"key":"bibr35-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2502-0"},{"key":"bibr36-1078155220973737","unstructured":"NeedyMeds. HealthWell foundation copay program\/patient access network foundation (PAN)\/Pfizer oncology together, www.needymeds.org\/generic-drug\/name\/glasdegib (accessed 6 February 2019)."},{"key":"bibr37-1078155220973737","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0373"},{"key":"bibr38-1078155220973737","unstructured":"BRIGHT MDS & AML 1012; NCT02367456 A combination study of PF-04449913 (glasdegib) and azacitidine in untreated MDS, AML and CMML patients (BRIGHT 1012), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02367456 (accessed 8 February 2019)."},{"key":"bibr39-1078155220973737","unstructured":"BRIGHT AML 1019; NCT03416179. A study evaluating intensive chemotherapy with or without glasdegib or azacitidine with or without glasdegib in patients with previously untreated acute myeloid leukemia (BRIGHT AML1019), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03416179 (accessed 16 September 2019)."},{"key":"bibr40-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-496596"},{"key":"bibr41-1078155220973737","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1578152"},{"key":"bibr42-1078155220973737","first-page":"53","volume":"12","author":"Wier P","year":"1990","journal-title":"Br J Pharm Pract"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220973737","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220973737","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220973737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:12Z","timestamp":1777688652000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220973737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1177\/1078155220973737"],"URL":"https:\/\/doi.org\/10.1177\/1078155220973737","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]}}}